Shoji K, et al. Clinical Characteristics of Hospitalized COVID-19 in Children: Report From the COVID-19 Registry in Japan. J Pediatric Infect Dis Soc. 2021 Dec 31; 10(12):1097-1100.
Walter EB, et al. Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age. N Engl J Med. 2022; 386:35-46.
Zambrano LD, et al. Overcoming COVID-19 Investigators. Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12-18 Years - United States, July-December 2021. MMWR Morb Mortal Wkly Rep. 2022; 71(2):52-58.
Fowlkes AL, et al. Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5–11 Years and Adolescents Aged 12–15 Years — PROTECT Cohort, July 2021–February 2022. MMWR Morb Mortal Wkly Rep. ePub: 11 March 2022.
Klein NP, et al. Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5-17 Years - VISION Network, 10 States, April 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022; 71(9):352-358.
Hause AM, et al. COVID-19 Vaccine Safety in Children Aged 5–11 Years — United States, November 3–December 19, 2021.MMWR Morb Mortal Wkly Rep. 2021; 70(5152):1755-1760.
Woodworth KR, et al.: The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5–11 Years — United States, November 2021.MMWR Morb Mortal Wkly Rep. 2021; 70(45):1579-1583.